The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas

References

• Athanassiadou P, Petrakakou E, Liossi A, Nakapoulou L, Zerva C, Dimopoulos A. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. Acta Cytologica 1999; 43: 1039–1044
   PubMed Web of Science ®Google Scholar
• Bokhman J V. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology 1983; 15: 10–17
   PubMed Web of Science ®Google Scholar
• Borazjani G, Twiggs J B, Leung B S, Prem K A, Adcock L L, Carson L F. Prognostic significance of steroid receptors measured in primary metastatic and recurrent endometrial carcinoma. American Journal of Obstetrics and Gynecology 1989; 161: 1253–1257
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Pileri S, Parravicini C, Becker M HG, Poggi S, Bifulco C, et al. Antigen unmasking on formalin fixed paraffin embedded tissue sections. Journal of Pathology 1993; 171: 83–98
   PubMed Web of Science ®Google Scholar
• Creasman W T, Soper J T, McCarty K S, Jr, McCarty K S, Sr, Hinshaw W, Clark-Pearson D L. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. American Journal of Obstetrics and Gynecology 1985; 151: 922–932
   PubMed Web of Science ®Google Scholar
• Ehrlich C E, Young P CM, Stehman F B, Sutton G P, Alford W M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. American Journal of Obstetrics and Gynecology 1988; 158: 796–807
   PubMed Web of Science ®Google Scholar
• Fakuda K, Mori M, Uchiyama M, Iwai K, İvasaca T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecologic Oncology 1998; 69: 220–225
   PubMed Web of Science ®Google Scholar
• Gal D, Recio F O, Zamurovic D, Tancer M L. Lymphvascular space involvement: A prognostic indicator in endometrial adenocarcinoma. Gynecologic Oncology 1991; 42: 142–145
   PubMed Web of Science ®Google Scholar
• Gehring P A, Le L Van, Olatidoye B, Geradts J. Oestrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86: 2083–2089
   PubMed Web of Science ®Google Scholar
• Geisinger K R, Homesley H D, Morgan T M, Kute T E, Marshall R B. Endometrial adenocarcinoma (a multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors). Cancer 1986; 58: 1518–1525
   PubMed Web of Science ®Google Scholar
• Hachisuga T, Kaku T, Fukuda K, Eguchi F, Emoto M, Kamura T, et al. The grading of lymphovascular space invasion in endometrial carcinoma. Cancer 1999; 86: 2090–2097
   PubMed Web of Science ®Google Scholar
• Kottmeier H L. Annual report on the results of treatment in gynecologic cancer. International Federation of Gynecology and Obstetrics, Stockholm, Sweden 1979; 17
   Google Scholar
• Kurman R J, Zaino R J, Norris H J. Endometrial carcinoma. Blaustein's pathology of female genital tract. 4th ed, R J Kurman. Springer, New York 1994; 439–486
   Google Scholar
• Lax S F, Pizer E S, Ronnett B M, Kurman R J. Comparison of oestrogen and progesterone receptor Ki-67 and p53 immunoreactivity in uterine endometrioid carcinoma with squamous, mucinous, secretory and ciliated cell differentiation. Human Pathology 1998; 29: 924–931
   PubMed Web of Science ®Google Scholar
• Marrett L D, Meigs J W, Flannery J T. Trends in the incidence of cancer of the corpus uteri in Connecticut 1964 – 1979, in relation to consumption of exogenous oestrogens. American Journal of Epidemiology 1982; 116: 57–67
   PubMed Web of Science ®Google Scholar
• Mittal K R, Schwartz P E, Barwick K W. Architectural (FIGO) grading and other prognostic indicators in stage I endometrial adenocarcinoma with identification of high risk and low risk groups. Cancer 1988; 61: 538–545
   PubMed Web of Science ®Google Scholar
• Morris P C, Anderson J R, Anderson B, Buller R E. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecologic Oncology 1995; 56: 406–411
   PubMed Web of Science ®Google Scholar
• Nielson A L, Nyholm H JC. Proliferative activity as revealed by Ki-67, p53 in uterine adenocarcinoma of endometrioid type: Comparison of tumours from patients with and without previous oestrogen therapy. Journal of Pathology 1993; 171: 199–205
   PubMed Web of Science ®Google Scholar
• Pichon M F, Broet P, Magdelanat H, Delarue J C, Spyratos F, Basuvau J P, et al. Prognostic value of steroid receptors after long term follow-up of 2257 operable breast cancers. British Journal of Cancer 1996; 73: 1545–1551
   PubMed Web of Science ®Google Scholar
• Salveson H B, Ýversen O E, Aksien L A. Prognostic significance of angiogenesis and Ki-67, p53 and p21 expression: A population based endometrial carcinoma study. Journal of Clinical Oncology 1999; 17: 382–390
   Web of Science ®Google Scholar
• Sasaki K, Murakami T, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. Journal of Cell Physiology 1987; 133: 579–584
   PubMed Web of Science ®Google Scholar
• Sherman M E, Bur M E, Kurman R J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorogenesis. Human Pathology 1995; 26: 1268–1274
   PubMed Web of Science ®Google Scholar
• Silverberg E, Lubera J. Cancer statistics. Cancer 1989; 39
   PubMed Web of Science ®Google Scholar
• Takama F, Kanuma T, Wang D, Kagami I, Mizunuma H. Oestrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer. British Journal of Cancer 2001; 84: 545–549
   PubMed Web of Science ®Google Scholar
• Yamauchi N, Sakamato A, Uozaki H, Lihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. International Journal of Gynecological Pathology 1996; 15: 202–208
   PubMed Web of Science ®Google Scholar
• Zaino R J, Kurman R J, Diana K L, Morrow C P. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group Study Cancer 1995; 75: 81–86
   Google Scholar